Rezolute reports validation of the potential use of rz358 for treatment of non-islet cell tumor hypoglycemia (nicth)

Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism)
RZLT Ratings Summary
RZLT Quant Ranking